MoneyWorks4Me

Kilitch Drugs(India) - Quaterly Results

08 Feb 2024 Evaluate
The company's total revenue for the quarter ended December 2023 saw a slight change in the total revenue, having registered a total revenue of Rs. 297.65 millions.A good growth in profit of 39.93% reported to Rs. 54.98  millions over Rs. 39.29 millions of corresponding previous quarter.Operating Profit saw a handsome growth to 74.13 millions from 53.28 millions in the quarter ended December 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 297.65 285.03 4.43 924.64 745.00 24.11 1177.84 1051.60 12.00
Other Income 33.95 11.13 205.03 52.92 31.66 67.15 45.98 45.59 0.86
PBIDT 74.13 53.28 39.13 202.67 136.51 48.47 217.71 155.54 39.97
Interest 5.35 2.77 93.14 13.39 5.78 131.66 9.85 6.63 48.57
PBDT 68.78 50.51 36.17 189.28 130.73 44.79 207.86 148.91 39.59
Depreciation 2.99 3.78 -20.90 8.35 9.63 -13.29 13.37 9.64 38.69
PBT 65.79 46.73 40.79 180.93 121.10 49.41 194.49 139.27 39.65
TAX 10.81 7.44 45.30 41.64 15.21 173.77 37.31 34.01 9.70
Deferred Tax -2.21 -7.01 -68.47 -8.87 -6.37 39.25 -4.66 -2.33 100.00
PAT 54.98 39.29 39.93 139.29 105.89 31.54 157.18 105.26 49.33
Equity 160.82 155.82 3.21 160.82 155.82 3.21 155.82 155.82 0.00
PBIDTM(%) 24.91 18.69 33.23 21.92 18.32 19.62 18.48 14.79 24.97
Peers
Company Name CMP
Sun Pharma. Inds. 1842.00
Dr. Reddys Labs. 1161.00
Cipla 1365.00
Lupin 2096.00
Zydus Lifesciences 1119.50
View more..